Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Akebia Therapeutics (AKBA) over the last 10 years, with Q3 2025 value amounting to $15.8 million.

  • Akebia Therapeutics' Change in Accured Expenses rose 60620.6% to $15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $39.5 million, marking a year-over-year increase of 38323.29%. This contributed to the annual value of -$12.8 million for FY2024, which is 2750.22% down from last year.
  • Per Akebia Therapeutics' latest filing, its Change in Accured Expenses stood at $15.8 million for Q3 2025, which was up 60620.6% from $16.0 million recorded in Q2 2025.
  • Over the past 5 years, Akebia Therapeutics' Change in Accured Expenses peaked at $30.8 million during Q3 2021, and registered a low of -$37.2 million during Q4 2021.
  • Moreover, its 5-year median value for Change in Accured Expenses was $519000.0 (2024), whereas its average is -$2.5 million.
  • Per our database at Business Quant, Akebia Therapeutics' Change in Accured Expenses plummeted by 44003.52% in 2023 and then surged by 298420.04% in 2025.
  • Akebia Therapeutics' Change in Accured Expenses (Quarter) stood at -$37.2 million in 2021, then skyrocketed by 55.7% to -$16.5 million in 2022, then surged by 122.55% to $3.7 million in 2023, then skyrocketed by 31.26% to $4.9 million in 2024, then skyrocketed by 224.59% to $15.8 million in 2025.
  • Its Change in Accured Expenses stands at $15.8 million for Q3 2025, versus $16.0 million for Q2 2025 and $2.8 million for Q1 2025.